Combined analysis of the microarray and drug-activity datasets has the potential of revealing valuable knowledge about various relations among gene expressions and drug activities in the malignant cell. In this paper, we apply Bayesian networks, a tool for compact representation of the joint probability distribution, to such analysis. For the alleviation of data dimensionality problem, the huge datasets were condensed using a feature abstraction technique. The proposed analysis method was applied to the NCI60 dataset (http://discover.nci.nih.gov) consisting of gene expression profiles and drug activity patterns on human cancer cell lines. The Bayesian networks, learned from the condensed dataset, identified most of the salient pairwise correlations and some known relationships among several features in the original dataset, confirming the effectiveness of the proposed feature abstraction method. Also, a survey of the recent literature confirms the several relationships appearing in the learned Bayesian network to be biologically meaningful.
Introduction
The enormous amount of biological data obtained from the high-throughput experimental techniques offers a new opportunity to molecular biology and medicine. For example, combined analysis of the microarray and massive drug-activity datasets can give an insight into various correlations among gene expressions and drug activities in the malignant cell.
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In this paper, we harness Bayesian networks to such analysis. Bayesian networks have mainly been used for the inference of gene networks from microarray data. [3] [4] [5] [6] [7] When adopting Bayesian networks for the analysis of huge biological data, the curse of dimensionality problem usually arises. To address this problem, we used a feature abstraction technique based on clustering to reduce the data dimensionality. The features, i.e. genes or drugs, are clustered according to their patterns over samples. Each resulting feature cluster maintains an abstract feature, called prototype, which is then used as a component (node) of the Bayesian network. It is expected that the established learning and probabilistic inference algorithms for Bayesian networks will be applicable through the feature abstraction. A similar approach was adopted for genetic network analysis using the graphical Gaussian modeling (GGM) technique in the work of Toh and Horimoto. 8 Their goal of data dimensionality reduction was to eliminate linear dependencies in the correlation coefficient matrix. Recently, Segal et al. 9 suggested a method for revealing gene regulation from gene expression profiles. They also adopted a clustering technique for identifying a set of co-regulated genes (modules). In contrast, the main purpose of data dimensionality reduction of our study is to make it feasible to analyze the massive biological datasets using Bayesian network learning. Moreover, we apply probabilistic inference for quantifying various relationships among genes, drugs, and cancer subtypes. Previous works did not exploit this feature of Bayesian networks for data analysis.
Materials and Methods

The NCI60 dataset
The NCI60 dataset 1 consists of 60 human cancer cell lines from 9 kinds of cancers: colorectal, renal, ovarian, breast, prostate, lung, and central nervous system origin cancers, as well as leukemias and melanomas. On each cell line, the gene expression pattern was measured by a cDNA microarray of 9703 genes including ESTs. Separate from this, 1400 chemical compounds were tested on the same 60 cell lines. The drug (chemical compound) activity on each cell line was measured by the growth inhibition activities (GI 50 ) assessed from changes in total cellular protein after 48 hours of drug treatment using sulphorhodamine B assay.
Before the analysis, we eliminated some genes and drugs for more reliable results. From 9703 genes, 1376 genes, having 4 or fewer missing values and showing strong variation among 60 cell lines (more than 3 measurements have red-green intensity ratios >2.6 or <0.38), were selected as in Scherf et al.'s work.
1 Furthermore, ESTs with no name were excluded from the analysis. From 1400 chemical compounds in the drug activity data, 118 anti-cancer drugs with known mechanisms were chosen for the analysis. Among them, drugs with more than 3 missing values were also thrown out. Consequently, the dataset in our analysis consists of 60 samples with 890 features: 805 gene expression levels in log 2 ratios, 84 drug activities in log 10 (1/GI 50 ) values, and one additional variable for the cancer type. Figure 1 outlines the entire analysis scheme for the NCI60 dataset. Fig. 1 . The analysis procedure for the NCI60 dataset. The original dataset is condensed through the feature abstraction procedure. Then, the Bayesian network is learned from the reduced dataset.
Bayesian networks for gene-drug dependency analysis
A Bayesian network compactly represents the joint probability distribution over a set of M random variables, X = {X 1 , X 2 , . . . , X M }:
where Pa S (X i ) denotes the set of parents of X i in the Bayesian network structure S, which encodes the conditional independencies among the variables in X, assuming a directed-acyclic graph (DAG) structure whose nodes are one-to-one correspondent to the variables. The conditional probability distribution P (X i |Pa S (X i )) is called the local probability distribution of X i . Figure 2 shows an example Bayesian network for gene-drug dependency analysis. Here, the DAG shows a dependency structure among gene expressions, drug activities, and the kind of cancer. For example, we could gain an insight that the kind of cancer (Cancer) influences the activity level of the drug D2 through the expression pattern of genes G1 and G2. Such a dependency can be quantified by calculation of the conditional probability (probabilistic inference).
The Bayesian network for gene-drug dependency analysis can be learned using a greedy search algorithm. 10 The greedy search is guided by a scoring metric such as the BD (Bayesian Dirichlet) score. 11 The BD score for the structure S given the training data D is defined as
where Θ denotes the set of the parameters for all the local probability distributions. With several assumptions such as i.i.d. complete data and Dirichlet prior, The local probability distribution of each node is represented as a table for the conditional probability distribution. The local probability distributions for G1 and D1 are not shown here.
the integral in Eq. (2) can be calculated in closed form as
where M is the number of variables of the Bayesian network, q i is the number of configurations of parents of X i , and r i is the number of values of X i . N ijk is the number of cases in D, where X i assumes its kth value when its parents assume their jth configuration. α ijk denotes the parameters of Dirichlet prior. N ij = k N ijk and α ij = k α ijk . Γ(·) denotes the Gamma function.
Feature abstraction for data dimensionality reduction
The scheme described in the previous section is not appropriate for the analysis of the massive biological datasets. One reason involves the inapplicability of the greedy search algorithm. The massive biological datasets usually have more than hundreds of data features. Because the space of the possible Bayesian network structures grows super-exponentially with the number of variables, a greedy search requires an extremely large amount of time. To make matters worse, the obtained solutions are likely to be very far from the global optimum. The search space of Bayesian network structures is known to be very complicated and multimodal, having many local maxima.
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Another reason is related with the infeasibility of probabilistic inferences. The memory requirement or the computation time of general probabilistic inference algorithms is usually exponential in the number of variables of the Bayesian network. Hence, the probabilistic inference to quantify the dependencies is impractical for Bayesian networks consisting of hundreds of variables. In order to mitigate these problems, we reduce the number of features in the massive biological datasets using a feature abstraction technique.
Formally, feature abstraction reduces an M -dimensional feature space X = (X 1 , . . . , X M ) into a K-dimensional prototype feature space F = (F 1 , . . . , F K ), where K M . In this paper, the meaning of feature abstraction is confined to aggregating individual features (genes or drugs) which show similar patterns in their properties, that is, transcriptional expression (genes) or activity (drugs) across samples. A prototype feature F k is defined by a partition subset B k of the original feature set X, where
For the feature abstraction, we tried two different clustering algorithms: k-means clustering 13 with the Pearson correlation coefficient and the sequential Information Bottleneck (sIB) method.
14 The k-means algorithm is a partitioning clustering algorithm, where the total within-cluster variance is tried to be minimized. The distance between a gene (drug) x and a cluster center (average value of the cluster) c was set to
where r(x, c) is the Pearson correlation coefficient between x and c. The Pearson correlation measure was chosen to group genes (drugs) which show similar relative, rather than absolute, variation pattern across patient samples. In terms of the metric between x and c, our clustering is closely related with the spherical k-means algorithm.
15
The sIB algorithm formulates the clustering problem in an information-theoretic view and runs like the sequential k-means algorithm. Let X and Y be the random variables representing the set of genes (drugs) x ∈ X and the set of tissue samples y ∈ Y, respectively. The cost of merging a gene (drug) x into a cluster c is given by
where JS(·, ·) is the Jensen-Shannon (JS) divergence.
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The number of clusters (prototype features) was set by a method based on random permutation of data. Here, correlation coefficients are first calculated for all of the permutated gene (drug) pairs, and a cut-off value θ is set in such a way that only upper α% of the values are higher than θ. Then, genes (drugs) in the original data are hierarchically clustered using an agglomerative method with average-linkage until all inter-cluster similarities are lower than θ. Finally, the number of clusters is set to the number of top-level subtrees in the dendrogram. a a This method is similar to the approaches in the works of Herrero et al. 17 and Lukashin and Fuchs 18 in that the number of clusters is determined using a random permutation-based test, but is different in that the cut-off value is applied at the level of clusters not of individual elements.
Original Dataset
Independent Clustering of Genes and Drugs Fig. 3 . Outline of the prototype dataset construction by feature abstraction. Genes and drugs are clustered independently, then prototype datasets are generated by feature averaging and feature sampling techniques, respectively. In feature averaging, the value of a prototype feature f i k (1 ≤ k ≤ K) of a sample S i is set to the average of expression (activity) values of the genes (drugs) in the cluster C k . In feature sampling, f i k is set to the value of a gene (drug) randomly chosen in C k .
Prototype dataset construction by feature abstraction
Let 805 genes and 84 drugs be clustered into K 1 and K 2 groups, respectively, such that the number of clusters is K = K 1 + K 2 in total. From the results, a condensed dataset with the reduced dimensionality (K + 1: the number '1' is added for the cancer type) is generated by feature averaging or feature sampling, which we call the prototype dataset hereafter. Figure 3 summarizes the prototype dataset construction process.
In the feature averaging approach, the original sample S i is transformed to S i of which the kth feature value f the expression (activity) values of genes (drugs) of the kth cluster. In the feature sampling approach, the kth feature value f i k of S i is set to the value x i j of an individual gene (drug) X j randomly selected from the cluster C k . The sampling process is repeated L times for each S i , by which L new prototype samples are generated from S i .
Learning Bayesian networks from the prototype dataset
As the local probability distribution model in learning Bayesian networks from the prototype dataset, we use the multinomial model which has mainly been adopted in the gene expression data analysis. 3-5,19b All the feature values in the prototype dataset were discretized for the multinomial model. We divided the feature values into three levels (low, normal, and high) based on the mean (arithmetic average) and standard deviation of each feature. Here, normal just denotes the value around the mean value across all the samples. The discretization boundaries were calculated as µ − b · σ and µ + b · σ, where µ is the mean value, σ is the standard deviation, and b is the constant which determines the breadth of the value normal. We tried several b values and set b as 0.60 in the experiments.
In the definition of the BD score in Eq. (2), P (S) denotes the prior probability of the structure S. We set P (S) ∝ 2
for penalizing the complex structures. The parameters for Dirichlet prior α ijk in Eq. (3) is set to the uninformative value 1.0. A greedy search algorithm 10 was adopted for the structural learning and the following constraints on the network structure were imposed to reduce the search space: 1) gene prototypes and drug prototypes can not be the parents of the cancer node, 2) drug prototypes can not be the parents of gene prototypes. The first constraint is based on the belief that the cancer type affects the gene expression patterns and the drug activities. The second is due to the nature of NCI60 dataset, where expression measurements of genes have been made on untreated cell lines, but not on those after the treatment by anti-cancer drugs, hence edges from a drug to genes are rather senseless. In addition, the maximum in-degree of the network is confined to two for compromising the extremely small sample size. Finally, to escape the local maxima that usually arise when relying on the greedy search, the greedy search with random restarts was run 20 times and the one with the highest BD score (Eq. (2)) was selected as an answer.
Results
Comparison with pairwise correlation analysis
First, we compare the results of our method with pairwise correlation analysis of the original dataset to investigate the influence of feature abstraction level (the number of prototype features) on the quality of the learned Bayesian network.
Distinct prototype datasets were generated with four confidence levels, α = 5, 10, 15, 20, in the random permutation-based test as described in the previous section about feature abstraction by clustering. The corresponding (# of gene prototypes, # of drug prototypes) were (55, 11), (34, 9), (24, 6) , and (16, 5) , where the cut-off value pairs were (θ gene , θ drug ) = (0.214, 0.218), (0.168, 0.169), (0.136, 0.134), (0.110, 0.110), respectively. In each case, two kinds of prototype datasets were constructed by averaging and sampling. In the latter approach, 100 subsamples were generated for each cell line (that is, L = 100 in Fig. 3) . Consequently, 16 prototype datasets, thereby 16 Bayesian networks, were constructed according to the number of clusters (4 cases), clustering method (2 cases), and the method for making prototype values (2 cases).
From the original dataset, the correlation coefficients for the following feature pairs were calculated. Among 323,610 gene-gene pairs, the top 5000 negativelycorrelated ones were tested. For drug-drug pairs, the top 50 negatively-correlated pairs out of 3486 pairs were examined. For 67,620 gene-drug pairs, the top 50 negatively-correlated pairs and the top 50 positively-correlated pairs were tested. For the comparison, we defined an information-theoretic measure based on the concept of conditional probability. Assume that gene A in the gene prototype G1 and gene B in the gene prototype G2 are highly negatively-correlated in the original dataset. Then, the measure for the negative correlation between G1 and G2 in the Bayesian network, N C(G1||G2) is defined as follows:
where JS(·, ·) is the JS divergence. The measure for the positive correlation, P C(G1||G2) is defined as the same as N C(G1||G2) except that the sign of the third term, JS(P (G1|G2 = low), P (G1|G2 = high)) is minus. The baseline for the two measures is when G1 and G2 are independent from each other, as well as P (G1|G2 = low) and P (G1|G2 = high) are Figure 4 shows the comparison results. In the figure, it can be seen that the quality of the learned Bayesian network is affected by the level of feature abstraction. As the number of prototype features increases, the positive and negative correlations are represented well in general. In the sequel, we present the analysis results using the model built by k-means clustering of 5% confidence level, (# of c In the case of the gene-gene (drug-drug) pair, positively correlated pairs are likely to be clustered into one gene (drug) prototype through the process of feature abstraction. Hence, we only consider negatively correlated gene-gene (drug-drug) pairs here. gene prototypes, # of drug prototypes) = (55, 11), with the sampling approach for prototype data generation, since it shows acceptable agreement with four kinds of pairwise correlations. The Bayesian network is shown in Fig. 5 . From this figure, we could gain insight on the dependency structure over gene prototypes, drug prototypes, and the cancer type, i.e. a condensed representation of the relationships among the features of the NCI60 dataset. Arbitrary conditional probabilities of interest can be calculated through the probabilistic inference, which is intractable on the Bayesian network consisting of hundreds of variables due to the exponential time/space complexity in the size of the network. 
Beyond pairwise correlations
Here, it is shown that more intricate relationships involving several features can be detected by our method. The target is two plausible relationships among gene expressions, drug activities, and the kind of cancer, obtained from Scherf et al.'s work. Figure 6(a) shows the part of the Bayesian network around the gene prototype G48 and the drug prototype D9 to which DPYD and 5-FU belong, respectively. To quantify the relationship among gene (G) expressions, drug (D) activities, and the kind of cancer (Cancer), we infer the probabilities P (G, D) and P (G, D|Cancer) from the Bayesian network. In specific, the probabilities for the following three cases according to the drug activities when the gene expression level is low or high are calculated:
, where P NEG (G, D) and P P OS (G, D) are the joint probabilities of G and D with negative and positive relations respectively, and P NEUT (G, D) is for the neutral case where drug activity is normal irrespective of the expression level of G. P (G, D|Cancer) is calculated in the same way as for P (G, D), except that each probability is conditioned on the specific kind of cancer. Figure 6 (b) shows the results of probabilistic inference on G48 and D9. Here, the negative tendency between G48 and D9 is observed well.
d Furthermore, this negative tendency becomes more definite when the kind of cancer is colorectal. For the cell lines of colorectal cancer where G48 is low, especially, the probability that D9 is high (P (G48 = low, D9 = high|Cancer = colon) = 0.387) is prominent compared to the probability that D9 is low (P (G48 = low, D9 = low|Cancer = colon) = 0.098). In the original dataset, in practice, all of the colon-derived cell lines show low expression level of DPYD and are highly susceptive to 5-FU. The d Considering the bias due to the randomness in the feature sampling approach, we generated the prototype datasets ten times and built Bayesian networks respectively from these ten datasets. The variations in the estimated probabilities were very small (all standard deviations were in the range of (0.001, 0.013)) and the mean probabilities for the 10 datasets are shown here. probabilities for G48 = high were not included in the result, since the probability P (G48 = high|Cancer = colon) inferred from the Bayesian network is so small (0.023) that it is statistically insignificant (actually, no high expression of DPYD are observed in colorectal lines of the original data set). The other relationship is among the expression of gene ASNS (asparagine synthetase Chr.7 [510206, (IW), 5 :AA053213, 3 :AA053461]), the activity of anticancer drug L-asparaginase, and the kind of cancer. L-asparaginase depletes the amino acid asparagine external to cells. Tumor cells, especially lymphatic tumor cells, need a great amount of asparagine for their growth. There exists a moderately high negative-correlation between the expression level of ASNS within tumor cells and the activity of L-asparaginase. Figure 7 shows the part of the Bayesian network around the gene prototype G44 and the drug prototype D11 that contain ASNS and L-asparaginase, respectively, and the inference results in the network. In Fig. 7(b) , it can be seen that P NEG (G44, D11) is higher than P P OS (G44, D11), where P NEG (G44, D11) = 0.184 and P P OS (G44, D11) = 0.142. For the leukemia cell lines, P NEG (G44, D11|Cancer = leukemia) = 0.318 and P P OS (G44, D11|Cancer = leukemia) = 0.263. The results accord with the negative tendency between the expression level of ASNS and the activity of L-asparaginase.
Exploratory analysis using Bayesian networks
In this section, we illustrate several salient features discovered by the Bayesian network described in the previous section and present the results of the literature survey related to them.
Relation between G17 and D10: The dependency structure for G17 and D10 is depicted in Fig. 8(a) . These two components are highly negatively-correlated (N C(G17||D10) is 0.720). However, the negative correlation seems to be mediated by other components, such as the kind of cancer and other genes in the Bayesian network. Eighteen genes in all belong to the prototype G17, including ITGB1 (integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) Chr. , and so on. The drug prototype D10 contains six drugs, where four members (paclitaxel, colchicine, trityl-cysteine, and vinblastine-sulphate) are tubulin-active antimitotic agents and the remaining two drugs are geldanamycin and bisantrene. Paclitaxel (taxol) is known to act as an anti-cancer agent by inducing microtubule stabilization or apoptosis of tumor cells. Two genes in G17, uPA and ITGB1, can affect the activation of paclitaxel in breast cancer cells, respectively. uPA catalyzes the conversion of plasminogen to plasmin. Plasmin induces the formation of multicellular spheroids of breast cancer cells, by which tumor cells get to acquire an increased resistance to chemotherapeutic drugs, including paclitaxel. 21 In the case of ITGB1, its signaling has been identified as an important survival pathway in drug-induced apoptosis in breast cancer cells. 22 Especially, the ligation of ITGB1 by extracellular matrix ligands can considerably inhibit apoptosis induced by paclitaxel. From these, it is expected that the chemotherapeutic effect of paclitaxel might be restrained by high expression of ITGB1 or uPA, by which the inferential negative relation between G17 and D10 in cells of specific cancer type (breast cancer cells, here) can be supported.
In fact, ITGB1 and paclitaxel are ranked at the 1st and the 2nd in the Pearson correlation similarity with the center profiles of G17 and D10, respectively. The uPA -paclitaxel pair is within the lowest-valued top ten among all member pairs, in terms of the JS divergence between its empirical probabilistic dependency profile and the inference result for G17 and D10 in the Bayesian network. The empirical pairwise dependency of a gene-drug pair is obtained directly from data, by calculating conditional probabilities based on their discretized patterns.
Relation between G2 and D4: Figure 8(b) shows the network structure around G2 and D4. These two nodes are directly linked in the network structure and also affected by the node of cancer type. These two prototypes are negatively correlated to each other (N C(G2||D4) is 0.685). G2 and D4 contain only one member, the gene BMI1 (murine leukemia viral (bmi-1) oncogene homolog Chr.10 [418004, (REW), 5 :W90704, 3 :W90705]) and the drug azacytidine, respectively.
The structure and functioning mechanism of the anti-cancer drug azacytidine (member of D4) are very similar to 5-aza-2 -deoxycytidine. And 5-aza-2 -deoxycytidine is known to promote the tumor suppressing protein p14/ARF, 23 whereas the gene BMI1 (member of G2) is known to negatively regulate p14/ARF.
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In the cancer cell line which shows high expression level of BMI1, it is anticipated that the functioning mechanism of azacytidine might not work because of the possibility of the interruption by BMI1, suppressor of p14/ARF. This hypothesis supports the observed negative correlation between the expression level of G2 and the activity of D4.
Discussion
We presented an analysis method using Bayesian networks that incorporates a feature abstraction technique to alleviate the curse of dimensionality problem, which thus makes it applicable to the analysis of massive biological datasets. The Bayesian network can capture the entire dependency structure immanent in the dataset. This property provides a means for encoding the valuable information contained in the large-scale datasets with noise. Further, the dependency among several features can be quantified by probabilistic inference. The probabilistic inference is used for calculating the conditional probability of interest, assisting the decision making.
It should be noted that our analysis is different from conventional regression or classification tasks, i.e. supervised learning. In our problem setting, any gene or drug prototype can be regarded as a dependent or an independent variable. In this sense, our method produces a huge number of dependency structures of similar shapes. To identify a small set of eligible ones among them, we exploited a measure for the negative correlation between gene and drug prototypes. The dependency structures with high negative-correlation (N C(·||·)) were examined by literature survey. Through this, we could confirm several dependency structures among gene expressions, drug activities, and the kind of cancer. Our findings were obtained in a purely data-driven way, and this demonstrates the potential of our method as an efficient data mining tool for the revelation of the relations between gene expression patterns and drug activities in cancer cells.
There are several directions for future work. One is to incorporate hidden nodes in Bayesian network learning so that discovery of more elaborated interactions among genes or drugs is possible. Another direction is to combine other information sources as prior knowledge. The protein-protein or DNA-protein interaction DB can be exploited for the more precise structural learning. Additionally, other sorts of data such as polymorphisms in key enzymes or gene expression patterns from cell lines treated with some drugs (e.g., expression profile data of responses to drugs, as in the work of Imoto et al. 7 , for cancer cell lines) could provide more biologically useful information.
